Effect of prophylactic anti-VEGF injections on the prevention of recurrent vitreous hemorrhage in PDR patients after PRP.
Angiogenesis Inhibitors
/ therapeutic use
Diabetic Retinopathy
/ therapy
Hemorrhage
/ drug therapy
Humans
Intravitreal Injections
Laser Coagulation
/ adverse effects
Neovascularization, Pathologic
/ drug therapy
Retrospective Studies
Vascular Endothelial Growth Factors
Vitreous Hemorrhage
/ etiology
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
25 08 2022
25 08 2022
Historique:
received:
30
03
2022
accepted:
21
07
2022
entrez:
25
8
2022
pubmed:
26
8
2022
medline:
30
8
2022
Statut:
epublish
Résumé
We evaluated the effectiveness of intravitreal anti-vascular endothelial growth factor (anti-VEGF) antibody injection (IVAI) for the prevention of recurrent vitreous hemorrhage (VH) due to neovascularization on disc (NVD) in patients with proliferative diabetic retinopathy (PDR) after panretinal photocoagulation (PRP). This retrospective case series reviewed the medical records of 12 PDR patients with recurrent VH after PRP from NVD. The interval between IVAIs was decided on the basis of the interval between VH recurrences after the initial IVAI, and NVD regression/recurrence during follow-up. We recorded the success rate of VH prevention, and the interval between IVAIs. Fundus examination revealed NVD regression at 1 month after the injection. However, NVD progressed gradually and VH recurred after 3-4 months. Thereafter, IVAIs were administered every 3-4 months; VH did not recur and visual acuity remained stable during the treatment period. In one case, NVD did not recur after 4 years of periodic injections. No systemic or ocular complications of IVAI were observed. In conclusion, proactive and periodic IVAIs (at 3-4-month intervals) may prevent recurrent VH in association with NVD in PDR patients after PRP.
Identifiants
pubmed: 36008505
doi: 10.1038/s41598-022-17214-y
pii: 10.1038/s41598-022-17214-y
pmc: PMC9411119
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Vascular Endothelial Growth Factors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
14484Informations de copyright
© 2022. The Author(s).
Références
Retina. 2006 Nov-Dec;26(9):1006-13
pubmed: 17151487
Ophthalmology. 1991 Oct;98(10):1575-9
pubmed: 1961647
Am J Ophthalmol. 2000 Feb;129(2):178-85
pubmed: 10682970
Eye (Lond). 2013 Dec;27(12):1391-6
pubmed: 24037235
JAMA Ophthalmol. 2018 Oct 1;136(10):1138-1148
pubmed: 30043039
JAMA. 2015 Nov 24;314(20):2137-2146
pubmed: 26565927
Ophthalmology. 1987 Jul;94(7):761-74
pubmed: 3658348
Lancet. 2017 Jun 3;389(10085):2193-2203
pubmed: 28494920
BMJ Open Ophthalmol. 2019 Dec 10;4(1):e000390
pubmed: 31909195
Int Ophthalmol. 2008 Feb;28(1):29-34
pubmed: 17619829